Topoisomerase IV, corresponding nucleotide sequences and...

Details Topoisomerase IV, corresponding nucleotide sequences and... Topoisomerase IV, corresponding nucleotide sequences and...

1999-09-17

2003-11-18

Hutson, Richard (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Isomerase

C435S183000, C435S194000, C530S350000, C536S023100, C536S023200, C536S023700

Reexamination Certificate

active

06649394

ABSTRACT:

The present invention relates to a novel topoisomerase IV, the nucleotide sequences encoding this enzyme, their corresponding vectors and the use of this enzyme for screening biologically active products.
Topoisomerases are enzymes capable of modifying the topological configuration of DNA rings, of making knots therein or of interlacing separated rings. They are thus involved in the replication, transcription and recombination of the entire genetic information (Wang et al., 1990). The mechanism of all these topological conversions is the same: the ring is opened so that a segment of DNA passes through the gap before the ends are rejoined. Two types of topoisomerase are involved in these conversions: type I topoisomerases which cut a single DNA strand and type II topoisomerases which cut both strands simultaneously.
Up until now, two type II bacterial topoisomerases have been identified and studied more particularly: gyrase from
Escherichia coli
(Gellert et al., 1976), and more recently, DNA topoisomerase IV from
E. coli
(Kato et al., 1990).
Gyrase is a &agr;
2
&bgr;
2
tetramer whose &agr; or GyrA and &bgr; or GyrB subunits are encoded by the gyrA and gyrB genes respectively. Bacterial gyrases are the only known topoisomerases capable of supercoiling relaxed DNA rings in the presence of ATP.
As regards more particularly DNA topoisomerase IV from
E. coli
, it relaxes supercoiled plasmid DNA, unknots T4 phage DNA and unwinds (or decatenates) kinetoplast DNA (Kato et al., 1992; Peng et al., 1993). The sequence of its corresponding genes, parC and parE from
E. coli
, has made it possible to demonstrate regions of high similarity between the subunits of gyrase and those of this topoisomerase IV, ParC with GyrA (35.6% over the entire sequence) and ParE with GyrB (40.1% over the entire sequence) respectively (Kato et al., 1990).
E. coli
gyrase has also been identified as being a primary target of fluoroquinolones (Hooper et al., 1993). It has thus been demonstrated that
E. coli
strains mutated at the level of the Ser83 residue in the GyrA subunit have a high resistance to fluoroquinolones (Maxwell, 1992). Fluoroquinolones bind less to DNA-mutated gyrase complexes than to DNA-wild-type gyrase complexes. Indeed, other point mutations, mapped in the region between residues 67 and 106 of GyrA, lead to strains resistant to fluoroquinolones. This region is called QRDR (Yoshida et al., 1990; Cullen et al., 1989). Similar results have been published with strains of
Staphylococcus aureus
resistant to fluoroquinolones (Goswitz et al., 1992; Sreedharan et al., 1990). Gyrase is therefore nowadays recognized as being the primary target of quinolones. However, a clinical strain of
Staphylococcus aureus
, not containing any mutation in the QRDR region of GyrA, has also been described as resistant to fluoroquinolones (Sreedharan et al., 1991).
Nowadays, this phenomenon of resistance developed by
Staphylococcus aureus
bacteria towards antibiotics and more particularly towards fluoroquinolones is being increasingly encountered at the therapeutic level. It would be particularly important to be able to lift this resistance and this involves a characterization of all the parameters which are associated with it.
The main objective of the present invention is precisely the identification, sequencing and characterization of nucleic sequences encoding subunits of a novel topoisomerase, topoisomerase IV of
Staphylococcus aureus
, composed of two subunits, GrlA and GrlB.
Unexpectedly, the applicant has found that the primary target of the fluoroquinolones in
S. aureus
is a topoisomerase IV and not gyrase. It has thus demonstrated that clinical strains of
S. aureus
, in which the QRDR region of the GyrA subunit of gyrase is identical to the wild-type sequence, develop nevertheless a resistance to fluoroquinolones because of a mutation which they possess in the region of the GrlA subunit of topoisomerase IV, homologous to the QRDR region.
The first subject of the present invention is a nucleotide sequence encoding at least one subunit of topoisomerase IV of
Staphylococcus aureus.
The present invention describes in particular the isolation and the characterization of the grlA and grlB genes. These genes have been cloned, sequenced and expressed in
E. coli
, and their enzymatic activity has been characterized. They were isolated from a
Staphylococcus aureus
genomic DNA library. From the grlAB nucleic sequence (SEQ ID No. 1 and SEQ ID No. 2), two open frames, corresponding to the grlB and grlA genes respectively, have been identified. The grlA and grlB genes have been sequenced in SEQ ID No. 4 and SEQ ID No. 6 respectively.
Preferably, the subject of the present invention is a nucleotide sequence chosen from:
(a) all or part of the grlA (SEQ ID No. 4) or grlB (SEQ ID No. 6) genes,
(b) the sequences hybridizing with all or part of the (a) genes and encoding a subunit of a topoisomerase IV, and
(c) the sequences derived from the (a) and (b) sequences because of the degeneracy of the genetic code.
It is clear that from the genes identified in the present application, it is possible, by hybridization, to directly clone other genes encoding a subunit of topoisomerase IV of bacteria close to
S. aureus
such as for example Streptococci and Enterococci. It is thus possible to clone this type of gene using, as probe, the genes grlA, grlB or fragments thereof. Likewise, the cloning of these genes may be carried out using degenerate oligonucleotides derived from sequences of the grlA or grlB genes or fragments thereof.
For the purposes of the present invention, derivative is understood to mean any sequence obtained by one or more modifications and encoding a product conserving at least one of the biological properties of the original protein. Modification should be understood to mean any mutation, substitution, deletion, addition or modification of a genetic and/or chemical nature. These modifications may be performed by techniques known to persons skilled in the art.
Among the preferred derivatives, there may be mentioned more particularly natural variants, molecules in which one or more residues have been substituted, derivatives obtained by deletion(s) of regions not or little involved in the interaction between the binding sites considered or expressing an undesirable activity, and derivatives having, compared with the native sequence, one or more additional residues.
Still more preferably, the subject of the invention is the nucleotide sequences represented by the grlA (SEQ ID No. 4) and grlB (SEQ ID No. 6) genes.
It also relates to any grlA gene having a mutation leading to a resistance to molecules of the quinolone and more particularly of the fluoroquinolone family. As a representative of these mutated genes, there may be mentioned more particularly the grlA gene having a base change from C to A at position 2270 of SEQ ID No. 4. The resulting gene is termed grlA
(C-2270A)
. This mutation leads to substitution of the Ser-80 residue with Tyr in the GrlA protein. The resulting protein will be designated by GrlA
(Ser-80 Tyr)
.
Another subject of the present invention relates to a recombinant DNA comprising at least one nucleotide sequence encoding a subunit of topoisomerase IV of
Staphylococcus aureus
. More particularly, it is a recombinant DNA comprising at least one nucleotide sequence as defined above in (a), (b) and (c) and more particularly the gene grlA (SEQ ID No. 4) grlA
(C-2270A)
and/or the gene grlB (SEQ ID No. 6).
According to a preferred mode of the invention, the nucleotide sequences defined above form part of an expression vector which may be autonomously replicating or integrative.
Another subject of the invention relates to the polypeptides resulting from the expression of the nucleotide sequences as defined above. More particularly, the present invention relates to the polypeptides comprising all or part of the polypeptides GrlA (SEQ ID No. 2) or GrlB (SEQ ID No. 3) or of their derivatives. For the purposes of the present invention, the term derivative designates any molecule o

Affiliated with

Also associated with

Rating

Topoisomerase IV, corresponding nucleotide sequences and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topoisomerase IV, corresponding nucleotide sequences and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topoisomerase IV, corresponding nucleotide sequences and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3136207